Rivaroxaban in nephrotic syndrome (RIPE) mechanistic clinical trial

The Defense Health Agency awarded the Research Institute At Nationwide Children's Hospital $5.795 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct RIVAROXABAN IN NEPHROTIC SYNDROME (RIPE), a mechanistic clinical trial.

The award funds a research project at the institute's Columbus, Ohio location, with performance extending through September 29, 2030. The assistance type is a Project Grant. The Research Institute At Nationwide Children's Hospital, a tax-exempt non-profit research subsidiary of Nationwide Children's Hospital, serves as the prime recipient and will conduct the clinical trial operations directly. The institute's federal research portfolio emphasizes biomedical and clinical research spanning pediatric oncology, neurology, infectious disease, cardiology, and rare genetic disorders, with substantial concentration in National Institutes of Health funding and emerging growth in Defense Health Agency support.